BACKGROUND: Despite evidence from clinical trials that intravenous (IV) thrombolysis is a cost-effective treatment for selected acute ischaemic stroke patients, there remain large variations in the rate of IV thrombolysis delivery between stroke services. This study is evaluating whether an enhanced care pathway delivered by paramedics (the Paramedic Acute Stroke Treatment Assessment (PASTA)) could increase the number of patients who receive IV thrombolysis treatment. METHODS: Study design: Cluster randomised trial with economic analysis and parallel process evaluation. SETTING: National Health Service ambulance services, emergency departments and hyper-acute stroke units within three geographical regions of England and Wales. Randomisation...
BACKGROUND: Stroke is a common cause of adult disability. Expert opinion is that about 20% of patien...
Background Stroke is a leading cause of death and disability internationally. One of the three effec...
Background: Thrombolysis using intravenous (IV) tissue plasminogen activator (tPA) is one of few evi...
BACKGROUND: Despite evidence from clinical trials that intravenous (IV) thrombolysis is a cost-effec...
BACKGROUND: Despite evidence from clinical trials that intravenous (IV) thrombolysis is a cost-effec...
Background Intravenous thrombolysis is a key element of emergency treatment for acute ischaemic stro...
BackgroundIntravenous thrombolysis and intra-arterial thrombectomy are proven emergency treatments f...
Background : Intravenous thrombolytic therapy (IVT) with tissue plasminogen activator for acute isch...
Background: Stroke is a leading cause of death and disability internationally. One of the three effe...
Background: Stroke is a leading cause of death and disability internationally. One of the three effe...
Objectives: To assess potential increases in intravenous thrombolysis (IVT) rates given particular i...
BACKGROUND: Expert opinion is that about 20% of emergency stroke patients should receive thrombolysi...
BACKGROUND: Stroke is a leading cause of death and disability internationally. One of the three effe...
Background. Time from acute stroke to enrolment in clinical trials needs to be reduced to improve th...
BACKGROUND Stroke is a leading cause of death and disability internationally. One of the three effec...
BACKGROUND: Stroke is a common cause of adult disability. Expert opinion is that about 20% of patien...
Background Stroke is a leading cause of death and disability internationally. One of the three effec...
Background: Thrombolysis using intravenous (IV) tissue plasminogen activator (tPA) is one of few evi...
BACKGROUND: Despite evidence from clinical trials that intravenous (IV) thrombolysis is a cost-effec...
BACKGROUND: Despite evidence from clinical trials that intravenous (IV) thrombolysis is a cost-effec...
Background Intravenous thrombolysis is a key element of emergency treatment for acute ischaemic stro...
BackgroundIntravenous thrombolysis and intra-arterial thrombectomy are proven emergency treatments f...
Background : Intravenous thrombolytic therapy (IVT) with tissue plasminogen activator for acute isch...
Background: Stroke is a leading cause of death and disability internationally. One of the three effe...
Background: Stroke is a leading cause of death and disability internationally. One of the three effe...
Objectives: To assess potential increases in intravenous thrombolysis (IVT) rates given particular i...
BACKGROUND: Expert opinion is that about 20% of emergency stroke patients should receive thrombolysi...
BACKGROUND: Stroke is a leading cause of death and disability internationally. One of the three effe...
Background. Time from acute stroke to enrolment in clinical trials needs to be reduced to improve th...
BACKGROUND Stroke is a leading cause of death and disability internationally. One of the three effec...
BACKGROUND: Stroke is a common cause of adult disability. Expert opinion is that about 20% of patien...
Background Stroke is a leading cause of death and disability internationally. One of the three effec...
Background: Thrombolysis using intravenous (IV) tissue plasminogen activator (tPA) is one of few evi...